California Institute for Quantitative Biosciences

NTT Research to Collaborate with Researchers at Harvard University on Computational Neurobiology

Retrieved on: 
Monday, January 24, 2022

NTT Research, Inc. , a division of NTT (TYO:9432), today announced that it has entered a joint research agreement with scientists at Harvard University to study animal neuro-responses with the hope of informing future artificial intelligence systems.

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced that it has entered a joint research agreement with scientists at Harvard University to study animal neuro-responses with the hope of informing future artificial intelligence systems.
  • In addition to the researchers at Harvard and the University of Tokyo, investigators at eight other universities have agreed to conduct joint research with the NTT Research PHI Lab.
  • NTT Research is part of NTT, a global technology and business solutions provider with an annual R&D budget of $3.6 billion.
  • NTT and the NTT logo are registered trademarks or trademarks of NIPPON TELEGRAPH AND TELEPHONE CORPORATION and/or its affiliates.

X-Therma Closes Oversubscribed $13M Series A Financing Led by LOREA AG

Retrieved on: 
Wednesday, December 22, 2021

X-Therma Inc. , a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation - has closed an oversubscribed $13M Series A funding round.

Key Points: 
  • X-Therma Inc. , a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation - has closed an oversubscribed $13M Series A funding round.
  • The financing is led by LOREA AG , an entrepreneur-operated investment firm, with participation from Zen11 Holdings, Graphene Ventures, VU Venture Partners, 2b AHEAD Ventures, Methuselah Foundation, Catalytic Impact Foundation, along with notable return angel investors.
  • X-Thermas turn-key solution XT-ViVo and TimeSeal in organ preservation removes this time constraint bottleneck without changing the peri-transplant workflow.
  • X-Thermas technology could be a paradigm shift that makes worldwide organ sharing possible and eliminates organ waiting lists across the globe.

Remix Therapeutics Appoints Zaven Kaprielian, Ph.D., as Chief Scientific Officer

Retrieved on: 
Wednesday, December 15, 2021

CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced the appointment of Zaven Kaprielian, Ph.D., as Chief Scientific Officer.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced the appointment of Zaven Kaprielian, Ph.D., as Chief Scientific Officer.
  • His considerable industry experience across several disciplines should be instrumental as we channel the power of our novel REMaster platform to bring new medicines to patients in need, said Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics.
  • Prior to Remix, Dr. Kaprielian was Chief Operating Officer, Project Chief Scientific Officer of Dementia Discovery Fund (DDF) U.S.
  • Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.

Stowers Institute recruits distinguished developmental biologist

Retrieved on: 
Wednesday, December 15, 2021

KANSAS CITY, Mo., Dec. 15, 2021 /PRNewswire/ --The Stowers Institute for Medical Research announced today that Tatjana Sauka-Spengler, PhD, a renowned developmental biologist who has led a research lab at the University of Oxford for the past ten years, will join the Institute in the first quarter of 2022.

Key Points: 
  • KANSAS CITY, Mo., Dec. 15, 2021 /PRNewswire/ --The Stowers Institute for Medical Research announced today that Tatjana Sauka-Spengler, PhD, a renowned developmental biologist who has led a research lab at the University of Oxford for the past ten years, will join the Institute in the first quarter of 2022.
  • She will also join the faculty of the Graduate School of the Stowers Institute.
  • "We are thrilled to welcome Tatjana and her lab to the Stowers Institute," said Institute Executive Director and Chief Scientific Officer and Howard Hughes Medical Institute Investigator Alejandro Snchez Alvarado, PhD.
  • "Joining the Stowers Institute is an outstanding opportunity for us to enhance our research programs by synergizing with the scientific expertise and technological capabilities at the Institute."

Capsida Biotherapeutics Announces Publication in Nature Neuroscience From Caltech Demonstrating Robust, Non-invasive IV Gene Delivery Targeted to the Brain While Avoiding Liver

Retrieved on: 
Thursday, December 9, 2021

For a genetic intervention to be safe and effective, a gene therapy should express a transgene in the affected brain cells while minimizing off-target expression.

Key Points: 
  • For a genetic intervention to be safe and effective, a gene therapy should express a transgene in the affected brain cells while minimizing off-target expression.
  • The research published in Nature Neuroscience describes how combinatorial AAV engineering of multiple loops was utilized to select capsids with brain-wide gene expression and liver detargeting after IV delivery in mouse and marmoset models.
  • These findings extended to non-human primates following IV administration, allowing for robust, non-invasive gene delivery to the central nervous system (CNS).
  • Capsida Biotherapeutics Inc. is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders.

Good Therapeutics Strengthens Senior Management Team with Two Appointments

Retrieved on: 
Thursday, December 9, 2021

Good Therapeutics, Inc. today announced appointments of Diane Hollenbaugh, PhD and Neela Patel, PhD to the companys senior management team.

Key Points: 
  • Good Therapeutics, Inc. today announced appointments of Diane Hollenbaugh, PhD and Neela Patel, PhD to the companys senior management team.
  • We are fortunate to have Diane at the heart of the Good Therapeutics management team.
  • Dr. Patel commented, Good Therapeutics has the magic combination of an innovative platform technology, a strong pipeline, a promising lead product, and most importantly, an outstanding leadership team.
  • A privately held company founded in 2016 and based in Seattle, Washington, Good Therapeutics is backed by a group of leading venture investors.

Covis Pharma Group Announces Two Executive Management Team Appointments

Retrieved on: 
Tuesday, December 7, 2021

ZUG, Switzerland, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, today announced the appointment of Raghav Chari as Chief Innovation Officer and Nicolas Verbeke as Senior Vice President, Europe & International. Both employees will report to Covis Pharma’s Chief Executive Officer, Michael Porter. Raghav joins with immediate effect and will be based in the U.S. Nicolas will join in early 2022 and will be based in Zug, Switzerland. 

Key Points: 
  • Both employees will report to Covis Pharmas Chief Executive Officer, Michael Porter.
  • Raghav Chari will be responsible for leading the worldwide lifecycle management of Covis Pharmas portfolio of medicines.
  • From 2009 to 2016, Raghav was President of Promius Pharma, a dermatology and neurology company, and Executive Vice President of Proprietary Products at Dr. Reddys Laboratories.
  • Before joining Covis Pharma, Nicolas was most recently the Vice President and General Manager, Europe, Middle East, and Africa, for Astellas Gene Therapies.

Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development

Retrieved on: 
Wednesday, November 17, 2021

RED BANK, N.J., Nov. 17, 2021 /PRNewswire/ --Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Jan Hillson, M.D., as Senior Vice President of Clinical Development.

Key Points: 
  • RED BANK, N.J., Nov. 17, 2021 /PRNewswire/ --Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Jan Hillson, M.D., as Senior Vice President of Clinical Development.
  • Dr. Hillson was most recently Senior Vice President, Clinical Development at Alpine Immune Sciences.
  • Dr. Hillson also served as Senior Vice Presidentof Clinical and Translational Research at ChemoCentryx.
  • As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products.

NASA Assigns Astronaut Jessica Watkins to NASA's SpaceX Crew-4 Mission

Retrieved on: 
Tuesday, November 16, 2021

WASHINGTON, Nov. 16, 2021 /PRNewswire/ -- NASA has assigned astronaut Jessica Watkins to serve as a mission specialist on the agency's upcoming SpaceX Crew-4 mission, the fourth crew rotation flight of the Crew Dragon spacecraft to theInternational Space Station.

Key Points: 
  • WASHINGTON, Nov. 16, 2021 /PRNewswire/ -- NASA has assigned astronaut Jessica Watkins to serve as a mission specialist on the agency's upcoming SpaceX Crew-4 mission, the fourth crew rotation flight of the Crew Dragon spacecraft to theInternational Space Station.
  • This will be Watkins' first trip to space following her selection as an astronaut in 2017.
  • Watkins joins NASA astronauts Kjell Lindgren and Robert Hines , as well as ESA (European Space Agency) astronaut Samantha Cristoforetti , as a crew member for the Crew-4 mission.
  • NASA previously announced the assignments of Lindgren and Hines as spacecraft commander and pilot, respectively, in February, and ESA announced Cristoforetti as a mission specialist for the mission in May.

L'Oréal USA Announces 2021 For Women In Science Fellows

Retrieved on: 
Monday, November 15, 2021

The 2021 L'Oral USA For Women in Science Fellows include:

Key Points: 
  • The 2021 L'Oral USA For Women in Science Fellows include:
    Julie Butler, whose research in neurobiology at Stanford University focuses on the brainhow it develops, how it influences behavior, and the role it plays in caregiver and infant bonds.
  • "As a company deeply rooted in science, L'Oral proudly recognizes and supports our 2021 For Women in Science Fellows who are pioneering research in their fields and serving as role models for the next generation of scientists," said Stphane Rinderknech, President & CEO, L'Oral USA.
  • "I'm honored to be recognized as a L'Oral USA 2021 For Women in Science Fellow.
  • For more information about the L'Oral USA 2021 For Women in Science Fellows visit: https://www.loreal.com/en/usa/pages/group/fwis/ .